Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05982873 | Expanded Access to Telisotuzumab Adizutecan | available | — | — | AbbVieINDUSTRY | 0 | Feb 6, 2026 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06370013 |
| Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors |
| available |
| — |
| — |
| TransThera Sciences (Nanjing), Inc.INDUSTRY |
| 1 |
| Apr 17, 2024 |
| clinicaltrials |
Data updated 22 days agoSource updated Feb 6, 2026source: clinicaltrials